In patients with ovarian cancer, SRPK1 has been found upregulated in 55% of tumor samples. In vitro experiments conducted with ovarian cell lines revealed that SRPK1 knockdown can lead to reduced cell proliferation rate, slower cell cycle progression, and compromised anchorage-independent growth and migration ability. The gene discussed is SRPK1; the disease is neoplasm.